Adaptimmune has more good news from its SPEAR T-cell therapy, yesterday unveiling encouraging early results in four patients with myxoid/round cell liposarcoma (MRCLS).
Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies, but at around one hundredth of the cost.
While CAR-T therapies could vastly improve outcomes in some types of blood cancer, finding ways to replicate this effectively and safely in solid tumours remains a challenge.
